Progress in the pathogenesis, clinical diagnosis and treatment of immune checkpoint inhibitor-related pneumonitis
- VernacularTitle:免疫检查点抑制剂相关肺炎的发病机制及临床诊治进展
- Author:
Aiping ZHANG
1
;
Jue CHEN
Author Information
- Publication Type:Research Article
- Keywords: immune checkpoint inhibitors; immune checkpoint inhibitor-related pneumonitis; non-small cell lung cancer; adverse effects; pneumonitis
- From: Journal of Clinical Medicine in Practice 2024;28(6):133-138
- CountryChina
- Language:Chinese
- Abstract: Immune checkpoint inhibitors (ICIs) are currently one of commonly used antitumor drugs in clinical practice, but they may trigger immune checkpoint inhibitor-related pneumonitis (CIP), thereby affecting the clinical benefits of patients. This article systematically analyzed domestic and foreign literature and summarized the research progress in the incidence, risk factors, pathogenesis, clinical manifestations, diagnosis, grading, and treatment of CIP. The paper aimed to timely intervene the occurrence and development of CIP and provided a reasonable and effective theoretical basis for the clinical application of ICIs.
